TESARO, Inc.
TESARO, Inc. (TSRO): 9 pipeline candidates · ~12 mo cash runway · 12 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
12.4 months
D/E -6.43 · 0% dilution
Lead: Approved
9 candidates
N/A
N/A
A transparent, data-derived signal for TESARO, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$485.7M
Quarterly Burn
$129.6M
Runway
12.4 mo
Revenue
$64.4M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (9 candidates)
| Drug | Phase |
|---|---|
| children's cetirizine hydrochloride hives relief | Approved |
| niraparib | Phase 3 |
| sodium | Approved |
| sodium chloride 0.9% in plastic container | Approved |
| tsr-022 | Phase 1 |
| tsr-033 | Phase 1 |
| tsr-042 | Phase 3 |
| varubi | Approved |
| zejula | Approved |
Frequently asked questions
How many drug candidates are in TESARO, Inc.'s pipeline?
TESARO, Inc. (TSRO) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is TESARO, Inc.'s lead drug candidate?
TESARO, Inc.'s most advanced tracked candidate is children's cetirizine hydrochloride hives relief (Approved) for Uses Temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose itchy, watery eyes sneezing itching of the nose or throat.
What is TESARO, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, TESARO, Inc. has approximately 12.4 months of cash runway.
Who is the CEO of TESARO, Inc.?
Leon O. Moulder, Jr. is the chief executive officer of TESARO, Inc. (TSRO).
Get the full picture on TESARO, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.